Hookipa Pharma, Inc. Forecast, price target & analysts
Hookipa Pharma, Inc. Target price 2025 - Analyst rating & recommendation
Hookipa Pharma, Inc. Classifications & Recommendation:
Hookipa Pharma, Inc. Price Target
| Target Price | $19.67 |
| Price | $1.50 |
| Potential |
1,211.11%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Hookipa Pharma, Inc. 2026 .
The average Hookipa Pharma, Inc. target price is $19.67.
This is
1,211.11%
register free of charge
$50.00
3,233.33%
register free of charge
$2.00
33.33%
register free of charge
|
|
| A rating was issued by 4 analysts: 2 Analysts recommend Hookipa Pharma, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hookipa Pharma, Inc. stock has an average upside potential 2026 of
1,211.11%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 20.13 | 43.07 |
| 41.26% | 113.97% | |
| EBITDA Margin | -404.27% | -114.60% |
| 17.17% | 71.65% |
4 Analysts have issued a sales forecast Hookipa Pharma, Inc. 2024 . The average Hookipa Pharma, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Hookipa Pharma, Inc. 2024 . The average Hookipa Pharma, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| EV/Sales | negative |
Based on analysts' sales estimates for 2024, the Hookipa Pharma, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Hookipa Pharma, Inc....
Current Hookipa Pharma, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 10 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Dec 20 2024 |
| JMP Securities | Locked ➜ Locked | Locked | Nov 21 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Dec 20 2024 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Nov 21 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Nov 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
